Hemogenyx Pharmaceuticals (LSE:HEMO) has reported progress in its Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia (AML) in adults. The company confirmed that the third patient treated in the study met the required safety benchmarks and showed encouraging early results, with no detectable AML cells following treatment. The trial is designed as a dose-escalation study, assessing safety as the primary endpoint, while also monitoring efficacy and survival outcomes. These initial findings highlight the therapy’s potential to address a serious unmet medical need and strengthen Hemogenyx’s position in the fight against aggressive forms of leukemia.
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in London, with subsidiaries in New York. The company is focused on developing novel therapies for blood and autoimmune diseases, leveraging proprietary product candidates and platform technologies to advance innovative treatment options.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply